What is structure-based drug design?

What is structure-based drug design?

• A. A form of target-centered drug design using the target’s 3D structure to design molecules that fit its active site.
• B. A method that uses the natural ligand as starting point.
• C. A high-throughput method using random screening.
• D. An approach based on known signaling pathways.

Answer: (A)

Structure-based drug design relies on the three-dimensional shape of the biological target to guide the creation of new compounds, aiming to fit precisely into the target’s active site. By using the target’s 3D structure—often obtained from X-ray crystallography, NMR, or cryo-EM—you can model how potential drugs would orient themselves and form key interactions (like hydrogen bonds, ionic contacts, and hydrophobic contacts). This approach lets you rationally optimize binding affinity and selectivity, iterating designs based on how well the molecules complement the active site geometry and chemistry. It’s a target-centered strategy that directly links the physical pocket of the protein to chemical design, rather than starting from known ligands or broad screening. The other options describe different strategies: starting from the natural ligand is a ligand-based approach that uses known binders rather than the target’s structure; high-throughput screening tests many random compounds without structural guidance; and a pathway-based approach focuses on signaling networks rather than direct binding to the target.

Structure-based drug design relies on the three-dimensional shape of the biological target to guide the creation of new compounds, aiming to fit precisely into the target’s active site. By using the target’s 3D structure—often obtained from X-ray crystallography, NMR, or cryo-EM—you can model how potential drugs would orient themselves and form key interactions (like hydrogen bonds, ionic contacts, and hydrophobic contacts). This approach lets you rationally optimize binding affinity and selectivity, iterating designs based on how well the molecules complement the active site geometry and chemistry. It’s a target-centered strategy that directly links the physical pocket of the protein to chemical design, rather than starting from known ligands or broad screening.

The other options describe different strategies: starting from the natural ligand is a ligand-based approach that uses known binders rather than the target’s structure; high-throughput screening tests many random compounds without structural guidance; and a pathway-based approach focuses on signaling networks rather than direct binding to the target.